Open Access
Subscription Access
Managing Cough Suppressants and Sedation in Cardiac Patients: A Human Perspective report
Abstract
In Cardiac patients, the administration of cough suppressant drugs needs careful consideration because of their potential effects on the Cardio vascular system. Cough suppressant, such as dextromethorphin and codeine are commonly prescribed to alleviate coughing associated with respiratory infections, allergies or chronic conditions like asthma. Sedatives, including benzodiazepines and opioid are often used to induce relaxation and manage anxiety or pain in patients. Close monitoring is essential when administering cough suppressants and sedatives to Cardiac patients. Finally it is concluded that balancing the need for cough suppression or sedation with safety of Cardiac patients needs careful consideration and vigilant monitoring by health care providers.
References
Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016 Aug;164:170-82. [PubMed]
Pioro EP. Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect. Neurol Ther. 2014 Jun;3(1):15-28. [PMC free article] [PubMed]
Patatanian E, Casselman J. Dextromethorphan/quinidine for the treatment of pseudobulbar affect. Consult Pharm. 2014 Apr;29(4):264-9. [PubMed]
Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016 Mar;159:1-22. [PubMed]
Corado CR, McKemie DS, Knych HK. Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration. Drug Test Anal. 2017 Jun;9(6):880-887. [PubMed]
Werling LL, Lauterbach EC, Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist. 2007 Sep;13(5):272-93. [PubMed]
Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997 Oct;62(4):400-7. [PubMed]
Tracy TS, Venkataramanan R, Glover DD, Caritis SN., National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005 Feb;192(2):633-9. [PubMed]
Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Dec 15, 2023. Dextromethorphan. [PubMed]
Lauterbach EC. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses. 2012 Jun;78(6):693-702. [PubMed]
Bem JL, Peck R. Dextromethorphan. An overview of safety issues. Drug Saf. 1992 May-Jun;7(3):190-9. [PubMed]
Ganetsky M, Babu KM, Boyer EW. Serotonin syndrome in dextromethorphan ingestion responsive to propofol therapy. Pediatr Emerg Care. 2007 Nov;23(11):829-31. [PubMed]
Prakash S, Rathore C, Rana K. The prevalence of serotonin syndrome in an intensive care unit: A prospective observational study. J Crit Care. 2021 Jun;63:92-97. [PubMed]
Chyka PA, Erdman AR, Manoguerra AS, Christianson G, Booze LL, Nelson LS, Woolf AD, Cobaugh DJ, Caravati EM, Scharman EJ, Troutman WG., American Assiciation of Poison Control Centers. Dextromethorphan poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007 Sep;45(6):662-77. [PubMed]
Refbacks
- There are currently no refbacks.